Eyenovia Provides Update on Phase 3 CHAPERONE Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Brookline Capital Markets Downgrades Eyenovia (EYEN) to Hold
November 15, 2024 9:24 AM ESTBrookline Capital Markets analyst Kemp Dolliver downgraded Eyenovia (NASDAQ: EYEN) from Buy to Hold.
The analyst comments "EYEN announced this morning that CHAPERONEs Independent Review Committee determined that the trial failed to meet the primary efficacy endpoint. As a result, the company will... More



